THE RECOVERY KERNEL

[illegible]

[illegible]

[illegible]

⚠ [illegible] ⚠

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible] [illegible] on 00.00. on [illegible], [illegible] on 00.00. [illegible]

[illegible] [illegible] on [illegible] [illegible] [illegible] [illegible] [illegible]-[illegible] [illegible] on [illegible] [illegible]

on [illegible] on on [illegible] [illegible] on [illegible] [illegible] [illegible] [illegible] [illegible] on [illegible] [illegible] [illegible] on [illegible] [illegible] [illegible] [illegible]

[illegible], [illegible] on 00.0. on

on [illegible] [illegible] [illegible] on on [illegible] on [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] on [illegible] [illegible] on [illegible]

[illegible] [illegible]

[illegible], [illegible], [illegible] on [illegible]

[illegible] [illegible], on on [illegible] [illegible] [illegible] on [illegible] [illegible] "[illegible]" on "[illegible] [illegible]" [illegible] [illegible]

[illegible] on [illegible] [illegible] [illegible] [illegible] on [illegible] [illegible] [illegible] on [illegible] [illegible] —

on [illegible] on [illegible] [illegible] on [illegible] [illegible] on [illegible] on [illegible]

on [illegible] [illegible] [illegible] on [illegible], [illegible] [illegible] [illegible]

The Feline Felonz

[illegible] [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] on [illegible] [illegible] [illegible]

---

on [illegible] [illegible], [illegible]

[illegible] on, [illegible] on [illegible] on [illegible] on [illegible] [illegible]

[illegible] [illegible]: "[illegible] [illegible] [illegible] [illegible]... [illegible] [illegible] [illegible]"

on [illegible] [illegible] [illegible]

on [illegible] [illegible] on [illegible] [illegible] on [illegible] on [illegible] [illegible]

[illegible] on [illegible], on [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

on [illegible] on [illegible] on [illegible] [illegible]

[illegible]

[illegible] *[illegible] [illegible] [illegible] [

□□□□□□□□□□□□□□□□□ □□□□ □□□□□□, □□ □□□□□□□ □□□□□□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□□□□□ □□ □□□ □□□□□□□□ □□□□□□□ □□ □□□ □□□□ □□□□□□

□□□□-□□□□

- □□□□□□ 1
- □□□□□□ 2
- □□□□□□ 3
- □□□□□□ 4
- □□□□□□ 1: □□□□□□□□□□ □□□□□ □□□□□□□□ □□□□ □□
- □□□□□□ 2: □□□□□□□ □□□□□□
- □□□□□□ 3: □□□□□□□ □□□□□□
- □□□□□□ 4: □□□□□□□□□□ □□□□□□
- □□□□□□ 5: □□□□□□□ □□□□□□
- □□□□□□ 6: □□□□□□□□□□ □□□□□
- □□□□□□□□ A: □□□□□□□ □□□□□□ □□□□□□□□
- □□□□□□□□ B: □□□□ □□□□□□ □□ □□□ AI □□□□□□ □□□□□

□□□□□ 1

□□□□□ □□□□□□□□□

□□□□ □□□□□□□□□□□□ □□□□□□□□□□ □□ □□□□□

□□□□□□□ 1.1: □□□□□□□□□□ □□□□□ □□□□□□□□ □□□□ □□

□ □□□□□□□□□□ □□ □□□ *□□□□□□ □□□□□ □□ □□□□ □□□□□□ □□□□ □□ □□□□□ □□□ □□ □□□□□□ □□□□□□□ □□□□□ □□ □□□ □□ □□□□□ "□□□□□□□□□□" □□ □□□□□ □□□ □□□□□□□□□□ □□, □□ □□? □□□ □□ □□□ □□□ □□ □□□□□□□□□□ □□ □□□□□ □□□ — □□ □□□ □□□□□□ □□ □□□□ □□□ □□ □□□□□ □□□□□□□ □□□ □□□□□ □□□*

□□□ □□□□□ □□□□□□ □□□□ □□□ □□ □□ □□□□□□ □□□□□□□□□□□ □□□□□□ □□□ □□□□ □□□□□□□□ □□□ □□□□□□□ □□□□□□□□□□ (□□□□□□□□□□□□□□□□□ □□□□□□□□), □□□□□□□□□□ □□□□□□□□ (□□□□□□□□□□□), □□ □□□□□□□ □□□□□□□□□□□ (□□□□□□□□□□ □□□□□□□) □□□□ □□ □□□□□□ □□ □□□□ □□ □□□□□□ □□□ □□□□□□□□□ □□□□ □□□□ □□, □□ □□□□ □□□□□□□□□□ □□□□□□ □□ □□□□ □□□

□ □□□□□□ □□□□□□□ — □□□□□□□□□ □□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□ □□ □□□□□□ □□□□□□□ □□ "□□□ □□ □□□□□□" □□ "□□□ □□ □□□□□ □□□□□" □□□ □□□ □□□□ □□□ □□ □□□□□□□

[illegible]

[illegible] 1.2: [illegible] — MTHFR

MTHFR [illegible] — [illegible] ([illegible]) [illegible], [illegible]

⚠ [illegible] **—** [illegible] 40-60% [illegible] MTHFR [illegible] "[illegible]", [illegible]

MTHFR C677T [illegible]:

• **C/C ([illegible]):** 100% [illegible]

• **C/T ([illegible]):** ~65% [illegible]

• **T/T ([illegible]):** ~30% [illegible]

[illegible] *MTHFR [illegible] 30% [illegible], [illegible] — [illegible] ([illegible]) [illegible]*

[illegible] 1.3: [illegible] — COMT

COMT [illegible] (Catechol-O-Methyltransferase) [illegible], [illegible]

[illegible]:

[illegible] **— VAL/VAL — '[illegible]'** [illegible] COMT [illegible]

□□□□ □□□ □□□□□□ □□□□□ □□□□ □□ □□□ □□□□ □□□□□□□□ □□ □□□□□□□□ □□□□ □□□ □□□□□: '□□□□□□□□' □□□□□ □□□□ □□ □□□ □□□□□□□ □□□□□□ □□□ □□□□ □□□ □□□: □□□□-□□□□□□□□□, □□□□ □□□ □□□□□

⚠ □□□□□□ □□□□□□□ **— VAL/MET —** '□□□□□□□' □□□□□□□□□ COMT □□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□□□□□ □□□ □□□□□□□ □□ □□□□ □□ □□□□□ □□□ □□□□□□ □□ □□□ □□□□□□ □□ □□□□ □□□

□ □□□□□ □□□□□□ □□□□□□ □□□□□ **— MET/MET —** '□□□□□' □□□□ COMT □□□□□□□□□□ □□□□□□□□ □□□ □□□□ □□□ □□□□ □□□□□□□ □□□□□□ □□□□ □□□□□□□ □□□ □□□□ □□□□□□□□□□□□ □□□□□□□ □□ □□□ □□□□□□ □□□□□ □□□□ □□□ □□□□ □□□□□□□□ □□□□ □□□ □□□□□: □□ □□ □□□□ □□□□ □□ □□□ □□□□□□ (□□□□, □□□□□□□□□□□□□□□□□, □□□□□) □□□ □□□□ □□□ □□□□□: □□□□□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□ □□□□

□ □□□□□□□□□□ □□ □□□ *□□□□□□ □□□□ □□□□□□ □□□□□□□ □□ □□□□: □□□□□□ □□ □□□□□□ □□□□□□□ □□ — □□□□□□□□□, □□□□, □□□□□□□□ □□□□ □□ □□□□□□□□ □□□□ □□, □□□□□□ □□□□□□ □□ □□□ □□ □□□□□□□ □□□ □□□□□ □□ □□□□□□ □□ — □□□ □□□□□□□□□□□□ □□□ □□□□□□□□□□ □□□□□□□□, □□□□□ □□□□□□□□ □□□□, □□□□ □□□□□□□□ □□ □□□□□□□□ □□, □□ □□□□□□ □□ □□□□ □□□□□ □□□□□ □□□ □□ '□□□□□' □□□□ □□□ □□ □□□□□□□ □□□□□□□□□□ □□ □□□ □□□□□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□ □□□□□□ □□ □□□□□□□ □□□□ □□ □□ □□ □□□□□□ □□□□□ □□ □□□□□□□ □□□ □□□□□□□ □□□□□□□ □□ □□□□ □□ □□□□□ □□□□ □□□*

□□□□□□□ 1.4: □□□□□□□□□□ □□□□□□ — CYP450

CYP450 □□□□□□ □□□□□□ (□□□□□ □□□ □□ CYP2D6, CYP3A4, CYP2C19) □□□□□□□□□□ □□□□ □□ □□ □□□□ □□□□ □□□□□ □□ □□□□□□□□ □□ □□□□ □□□□□□□ □□□□ □□□ □□□□ CYP450 □□□□□□ □□ '□□□□□□□' □□□□□ □□ □□□□□□□□ □□ □□□□ □□□ □□□□ □□□

CYP2D6 □□□□□□□□□□:

□ □□□□□ □□□□□□ □□□□□□ □□□□□ **—** □□□□ □□□□□□□□□□□□ **(PM)** □□□□□□ □□□□□□□□□ □□□ 1-2% (□□□□□□□□ □□ □□)□ CYP2D6 □□□□□□ □□□□□□□□□□□ □□ □□ □□□□□ □□□□□□ □□□□ □□ □□□ □□ □□□□ □□□□ □□□□□ □□□ □□□□ □□□□□□ □□□□ □□□□ (□□□□□□□ □□□ □□□□□□□□□ □□□□ □□ □□□□)□ □□□□□□□□ (□□ CYP2D6 □□ □□□□□□ □□□□ □□) □□□□ □□□□ □□ □□□ □□□□ □□□ FDA □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□ □□□□□□□: PM □□□□□□□ 60+ □□□□□ □□ □□□ □□□□□□□ □□□ □□ □□□□□□□□□ □□□

□ □□□□□ □□□□□□□ **—** □□□□□□□ □□□□□□□□□□□□□ **(NM)** □□□□□□□ □□□□□□□ □□□□ □□□□□ □□□□ □□□□ □□□ □□ □□ □□□□ □□ □□□□□ □□□ □□□ □□□□□□□ □□□□□□□ □□□ □□□□ □□□□

⚠ [illegible] — [illegible] **(IM)** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] — [illegible]-[illegible] [illegible] **(UM)** [illegible] [illegible] [illegible] 1-2%[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [

⚠ [illegible] — [illegible] [illegible] MTHFR [illegible], [illegible] [illegible] '[illegible]' [illegible] [illegible] 30-70% [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] 5-7 [illegible], [illegible] 2-3 [illegible] [illegible]

[illegible] 1: [illegible]-[illegible] (3-7 [illegible])

[illegible] — [illegible] • [illegible] (400-600mg/[illegible]): [illegible] • C (1000-2000mg/[illegible]): [illegible] • [illegible]-[illegible] (600mg) + ALCAR (500mg): [illegible] • NAC (600-1200mg/[illegible]): [illegible] — [illegible] 24-48 [illegible]

[illegible] 3: [illegible]-[illegible] [illegible] ("[illegible]")

[illegible] **5-HTP** [illegible] MDMA [illegible] 24 [illegible] 5-HTP [illegible]; 48 [illegible]

[illegible] — [illegible] **(24-48** [illegible]**)** • 5-HTP (50-100mg) + EGCG (400mg): [illegible] • L-[illegible] (500-1000mg): [illegible], [illegible] • B-[illegible] ([illegible]): [illegible] • [illegible]-3 (2-3g EPA+DHA): [illegible]

[illegible] 3

[illegible] 6.7: E.K.G. [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

E + K = [illegible] **| E + G =** [illegible] **| K + G =** [illegible]

[illegible]**:** E = [illegible]/MDMA | K = [illegible] | G = GHB/[illegible]

[illegible] [illegible]

	MDMA	□□□□□□	□□□□□□□ □□	**GHB**	□□□□	□□□□
MDMA	---	□ □□□□□□□□ □	□ □□□□□	□ □□□□□□□	□ □□□	□ □□□
□□□□□□	□ □□□□□□□□ □	---	□ CK	□ □□□□□□□ □	□ □□□	□ □□□□□□
□□□□□□□ □□	□ □□□□□	□ CK	---	☠ □□□□	□ □□□□□	☠ □□□□□
GHB	□ □□□□□□	□ □□□□□□□ □	☠ □□□□	---	□ CNS	☠ □□□□
□□□□	□ □□□	□ □□□	□ □□□□□	□ CNS	---	□ □□□□□
□□□□	□ □□□	□ □□□□□□	☠ □□□□□	☠ □□□□	□ □□□□□	---

□□□□□□:

□ □□□: □□ □□□□□ □□□□□ (□□□ □□ □□□□□□□□ □□□□)

□ □□□□: □□□□□□□ — □□□□ □□□ □□□□□, □□□□□□□ □□ □□□□□□

□ □□□: □□□□□□ — □□□□□□□□□ □□□□□ □□ □□□□□

☠ □□□□□□: □□□□□□□ □□□□ — □□□□□□ □□□□

⚠ □□□ □□□: □□□□□ □□□ □□□□□□□□

□□□□□□□ □□□□

□ □□□□□ □□□□□ □□□□□ □□□□□ — □□□□□ **+ MDMA/**□□□□□□ □□□□□□□□ □□□□□□□ + □□□□□ □□□□□□□ □□□□□ □□□□□ □□□□ □□ □□□□ □□ □□ □□□□ □□□ MDMA □□□□□□□□□□□□ □□ □□□□ □□□□ □□□ □□□□□□□: □□□ □□□□□□□□□ □□ □□□□□ □□□□□□□□ □□□□□ □□ □□□□□□□□

□ □□□□□ □□□□□ □□□□□ □□□□□ — □□□□□□□□□□□ **+ MDMA:** □□□□, □□□ □□□□□□□□, □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □□ □□□□□□□□ □□□□ □□□ MDMA □□□□□□ □□□□□□□□ □□ □□□□□ □□□□ □□□

□ □□□□□ □□□□□□ □□□□□□ □□□□□ **— MAOIs +** □□□ □□ □□□□□□□□□□□□ □□□□□□ MAOIs □□□□□□□□□ □□ □□□□□ □□ □□□□□ □□□□ □□□ □□ □□□□□□□□□-□□□□□□□□□ □□□□□□ □□□□□□ = □□□□□□□□□ □□□□□ □□□□□-□□□□□ □□□□□□□□ □□□□□□□

□ □□□□□ □□□□□□ □□□□□□ □□□□□ **—** □□□□□□□□□□□□□□ **+** □□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□ + □□□□□□□□ □□□□□□ = □□□□□□□□□□□□ □□□□□□□□□

"□□□□□ □□□□□" □□□□□□

□□□□□□ □□□□□ □□ □□□□: □□□□-□□□□□□□ □□ □□□□□□□□ □□□

□□□□□ □□ □□□□□□□□□□

□ □□□□□□□□□□ □□ □□□ *□□ □□□□□□□ □□ □□□□□□□ (+1) □□□□ □□□□□□ (-1) □□□□□ □□□□ (0) □□□□□□□□□ □□□ □□ □□□ □□□ □□ □□ □□ □□ □□□ □□□ □□□□□□□□□□ □□□□□ □□□ □□ □□□□□ □□□□□ □□□, □□ □□□□ □□□□ □□ □□□□ □□□□ □□□ — □□ □□□□□ □□ □□□□□ □□□ □□□□□□□□□ □□□□□ □□□ □□□□□□□□□□ □□□□ □□□□□□□□□□ □□□□ □□□□□ □□□□ □□□ □□□□ □□□ □□□□ □□□ □□□□ □□□□□□□□□□ □□□□□□□□□□ □□□ □□□□□□ □□□□□□ □□□□*

□ □□□□□ □□□□□□ □□□□□□ □□□□□ **—** □□□□□□ □□□□□□ □□□□ □□□ □□ □□□□□□□ □□□ □□□□ □□□ □□ □□□□□□ □□□□□□ □□□□□ □□□□□ □□□ — □□□□ □□□ □□□ □□ □□□□ □□□□ □□□□ □□□□ □□□□□□□□ □□ □□□□□□□ □□□□ □□ □□□□□ □□ □□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□□□ □□ □□□□□ □□ □□□□ □□□□ □□□□ □□ □□□□ □□□□□ □□□□ □□□□□□□□□□ □□ □□□□□□□□□□ □□ □□□□ □□□□ □□□□□

"□□□□" □□□□□□□ **—** □□□□□□□□ □□□□□ □□ □□□□□ **GHB**

□□ □□□□□□ □□ □□□□□□ □□□□ □□□□ □□□ □□ □□□□□ (□□□□□□□ □□) □□□□ □□□ □□□□ □□ **—** □□□ □□□ □□ □□□ □□, □□□□ □□□□□□ □□□ □□□□□ □□□□□ (GHB) □□□□ □□□□ □□□□□□ □□ **—** □□□ □□□□ □□ □□□ □□, □□□□ □□□□ □□□ □□ □□ □□□□□ □□□ □□□ □□□, □□ □□□□□□□□ □□□□

"□□□□□□□□□ □□□□□ □□□□□□□□□□□" **—** □□□□ □□□□□□□□

□□□ □□□ □□□□□ □□ □□□□□□□□□□□ □□□□□□ □□□□ □□ □□ □□□□ □□□ □□ '□□□□□□□□' □□□□ □□ □□□ □□□□ □□□□□□□□ □□□□ □□□□ □□□□ □□□□□□□ □□ □□□□□ □□□□□□□ □□ □□□□ □□□

□ □□□□□□□□□□ □□ □□□ *□□□□□□□ □□ □□□□□□ □□□□□□ □□□□ □□□: □□□□□ □□□□□□□□□□ (□□ □□□□ □□□□□□□□ □□ □□□□□□□ □□□□ □□□) □□ □□□□ □□□□□□□□□□ (□□ □□□ □□ □□□□ □□ □□□ □□□□□ □□□)□ □□□□ □□□□□□□□ □□□ □□ □□□□□ □□□ □□□□□*

*[illegible] [illegible] [illegible] [

□□□□□□□□ □□□□□□□□□□: CYP2C19 □□□□ □□□□□□□□□□□□□ + □□□□□□-□□□□□□□□□□□□□□□□ □□□□□□□□

⚙ □□□□□□□ □□□□□□□ □□□□□□□□□: □□□□□□□ □□ □□ □□□□□□□□□ □□ □□□□□□□□□□□□□□□□□□ □□□□□□ □□ □□ □□□□□□ □□□□ □□ □□□ □□ — □□□□ '□□□□□□□ □□□□□□□'□ □□□□□ □□□□□□□□ □□ □□□□□□ □□ □□□□□□□□ COMT Met/Met □□□□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□□□□□□□□□□□□□□ □□ □□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□ □□□□ CYP2C19 □□□□□□□□□□ □□□□□□□□□□□□□□ □□ □□□□□□□ □□□□ □□ □□□□□□□□□ □□□□□ □□□□□ □□ □□□□□ □□□□□□□□□□□□□ '□□□□□□□□' □□□□□□ □□ □□□□□□□□ □□□□□ □□ □□□□ □□□□□ □□□□

□ □□□□□□□ □□□□□□□□□□: □□□□□□□□ □□□□□□□□□□□□□□□□□□ □□ CYP2C19 □□□□□□□□ □□ □□□□□ □□ □□□□ □□□□□ □□ □□□□□□ □□□□□□□ □□□□□□ □□ 36 □□□□□ □□ □□□□□

□ □□□ □□□□□□□: □□□□□□□ □□□□

□ □□□□□□-□□□□□□□ □□□□□: □□□□□□□ **(1958-2016)**

□□□□□□□ □□□□: **CYP2D6** □□□□□ □□

□□□□□□□□□ □□□□□□□ □□□□□: □□□□□ □□□□□□□□ □□ □□□□□□□□□ □□□□□□□□

□□□□□□□: □□□□□□□□□ (□□□□□ □□ □□ □□□□□□□□ □□)

□□□□□□□□□ □□□□□□□□□□: CYP2D6 □□□□□ □□□□□□□□□□□□□□ → □□□□□ □□□□□□□□□ □□□□□□□□□ → □□□□□□□ □□□□□

⚙ □□□□□□□ □□□□□□□ □□□□□□□□□: □□□□□□□ □□ □□□□□□□□ □□□□ □□□□ □□□□ FDA □□□□□□□□□□□□□□□ □□ □□□□□□□, CYP2D6 PMs □□ □□□□□□ □□ □□□□ □□□□□ □□□□□ □□□□□□ (□□□□□□□□ □□□□ □□□□□□□□□□ □□□□□ □□ □□□□□) □□□□□□ □□□□□□□□□ □□ □□□□□ □□□□□□□ (CYP2D6 □□ □□□□□□□ □□□□□ □□)□ □□□□ □□ PM □□, □□ □□□□□ □□□□□□□□□ □□□□□ □□□□ □□□□□ □□□□, □□□□□□□ □□□□□□□□ □□□□□□□□ □□ □□ □□□□□□□

□ □□□□□□□ □□□□□□□□□□: □□ ₹25,000 CYP2D6 □□□□□□ □□□□□ □□□□□□□ □□□□ □□ □□□□□□□□□□□ □□ □□□□□ □□□□

□ □□□□□□-□□□□□□□ □□□□□: □□□□□□□ □□□□□ **(1969-2023)**

□□□□□□□ □□□□: □□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□

□□□□□□□□□ □□□□□□□ □□□□□: □□□□□□□□□ □□ □□□□□□ □□□□□□□, □□□□□□, □□□□□□□□ □□□□□□□ □□□□□□, □□□□□□□□□□□□□□□□

□□□□□□□: □□□□□□□□□ (□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□ □□ □□□□ □□) + □□□□ □□

□□□□□□□□ □□□□□□□□□□: CYP3A4/CYP2B6 □□□□□□ + □□□□□-□□□□□□□□□□ COMT/MTHFR □□□□□□□□□

⚙ □□□□□□ □□□□□□ □□□□□□□□□: □□□□ □□□□ □□□□□□□□: □□□□□□ □□ □□□□□□ □□ □□□□□□ □□ □□□ □□ □□ □□□ □□□□□□□□ □□□□□ □□ □□□ □□□ □□□□□□□ □□ □□□ □□□ □□□□ □□□□□-□□□□□□□□□□ □□□□□□□□ □□ □□□□□□□□ □□□□□□ □□ □□□□□□□□□□ □□ □□□□ □□□□ □□□□□ □□□□□□□□ + □□□ □□ + □□□□□□□ □□□□□□ □□□□□ + □□□□□□□□□□□□□ = □□□□□ □□□ □□□□□□ □□ □□□□□□ □□□□□ □□ □□□□□ □□, □□□□ □□□□□□ □□□□ □□□□ □□□□□ □□ □□□□ □□□□□□

□ □□□□□□ □□□□□□□□□□: □□□□□□□□ □□□□□□□□□ □□ □□ □□□ □□□□□□□□□□□□□□□ □□□□□□□□ □□□ □□ □□□□□ □□ □□□ □□□□□□ □□□□□□□□□□ □□ 54 □□□□ □□ □□□

□ □□□□□ □□□□□□ □□□□□□ □□□□□ — □□□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□ □□□□ □□ □□□□□□ □□□□□□□□□□□ □□□□□□□□ □□ □□□□□ □□□□ □□□□ □□ □□□□ □□ □□□ □□ □□□□□□□ □□: □□ □□□ □□□□ □□□ □□ □□□ □□ □□ □□□□ □□□ □□□□ □□ □□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□-□□□□□ □□□□ □□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□ □□□□ □□□□□ □□□□ □□□□□□□□□□ □□ □□□□□□ □□□□ □□ □□□ □□□□□ □□□ □□□□□ □ □□□□□

□□□: □□□□ □□□ □□ □□ □□ □□□□ □□□ □□□□ □□

1962 □□□ □□□□□□ □□□□□ □□ 2023 □□□ □□□□□□ □□□□ □□ — □□□ □□□ □□ □□□□□□ □□□□□ □□□□□□ □□□ □□□□□□□ □□□ □□□□□□□□□□ □□□ □□□□□□□□□□□□□□□ □□□ □□ □□□□

□ □□□□□□□□□□ □□ □□□ *□□ □□□□□□ □□□ □□□□□□□□ □□□□□□□ □□□□ □□□ □□ □□□□□ □□□□ □□□ □□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□ □□□□□□ □□□ □□□□ □□□□□□□□ □□ □□□□ □□□□ '□□□ □□ □□□ □□□□ □□□□□□□□ □□ □□□ □□□ □□□□ □□?' □□□□ '□□ □□□□□ □□ □□□ □□ □□□ □□□□□□□□□□□□□ □□□□ □□□?'*

□ □□□□□ □□□□□□ — □□□□□□□ □□□□□ □□ □□ □□□□□□□□□□□□□□□□ □□□□ □□ □□□□ ₹15,000-40,000 □□□ □□□□ COMT, CYP450, MTHFR, OPRM1 □□□□□□□□□□ □□ □□□□□ □□ □□□ □□ □□ □□□□□□□ □□ □□□□□□□□ □□□ □□ □□□□□□□ □□□ □□□□□ □□ □□□□□□ □□□□□□ □□ □□□ □□ □□□□ □□ □□□□ □□□

□□□□□□ 1: □□□□□□□□□□ □□□□□ □□□□□□□□ □□□□ □□

□□□ □□ □□□□□□□□□ □□□□□□□ □□□□

1.1 [illegible]

[illegible] *[illegible] [illegible], [illegible] '[illegible] [illegible] [illegible]' [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible], CEOs [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible]*

[illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] '[illegible] [illegible] [illegible]' [illegible] '[illegible] [illegible]' [illegible] [illegible] [illegible] [illegible]' [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible]

1. [illegible] **(MTHFR)** — [illegible]
2. [illegible] **(COMT)** — [illegible]
3. [illegible] **(CYP450)** — [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible]

1.2 [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: • [illegible] = [illegible] [illegible] [illegible] [illegible] [illegible] • [illegible] = [illegible] [illegible] [illegible] [illegible] • [illegible] = [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] • [illegible] = [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] 2: [illegible] [illegible]

MTHFR [illegible] [illegible]

2.1 MTHFR [illegible]?

MTHFR □□□ (Methylenetetrahydrofolate Reductase) □□ □□□□□□ □□ □□□□□ □□□□ □□ □□ □□□□□ □□ □□□□ □□□□□□ □□□ □□□ □□□□□□□□□ □□□□ □□: **L-**□□□□□□□□□□□ □□ □□□□□□ □□□ □□□□□□ □□:

• □□□□□□□□□ □□ □□□□□□□ (□□□, □□□□, □□□□□□) • □□□□□□□□ □□ □□□□□□□ (□□□□□□□, □□□□, □□□□) • □□□□□□□□□□□□□ □□ □□□□□□□ (□□□□□, □□□□□□□) • □□□□ □□□□ □□□ □□□□□□□□ □□□□□□□□□□□□□

2.2 □□□□□□ □□ □□□□□□

C/C □□□□□□□□ (□□□□□□ □□□□)

□ □□□□□ □□□□□□ — □□□□□□□ □□□□□ • 100% □□□□□□ □□□□□□ • □□□□ □□□□□ □□□□□□ □□ □□□□□□□□ □□□□ □□ • □□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□ □□□ □□ □□□ □□□□□ □□ • □□□□ □□□□□□□□□□□□□□□□ □□ □□□ □□ □□□□□□□□ □□□ □□ □□□ □□□□ □□□

C/T □□□□□□□□ (□□□□□□□□□□□□□)

⚠ □□□□□□ □□□□□□□ — □□ □□□□□ • ~65% □□□□□□ □□□□□□ • □□□□□□□□□□ □□□□□□□□□□□ □□ □□□□□□□ □□ □□□□ □□ • □□□□□□□□□□□□□□□ □□□□□ □□□ □□ □□□□□□□ □□ □□□□ □□□ • □□□□□□□□/□□□□□ □□ □□□□□ □□□□□ □□□□□□□

T/T □□□□□□□□ (□□□□□□□□□□)

□ □□□□□ □□□□□□ □□□□□□ □□□□□ — □□□□□ □□□ □□ □□ □□□□□ • ~30% □□□□□□ □□□□□□ • □□□□□□□□□□□□□□□□ □□□□□□□ □□□□ □□□□□□ □□□□ □□□ □□ • □□□□□□□□□□ □□□□□□□□□□□□ □□ □□□□ □□□□□□□□□□□□□□□□ □□□□□ □□□□ □□□□ □□□ • □□□□□□□□□, □□□□□ □□ □□□-□□□ □□ □□□□□ □□□□ □□□□□□□

2.3 MTHFR □□□□□□□□□□□ □□□□□□□□□

□ □□□□□ □□□□□□ — **T/T** □□ □□□ □□□□□□□ □□□□□ • **L-**□□□□□□□□□□ (400-800 mcg/□□□, □□□□-□□□□ 15mg □□ □□□□□□ □□□ □□□ □□) • □□□□□□□□□□□□□□ **(B12)** (1000-5000 mcg/□□□) • **P-5-P (**□□□□□ **B6)** (25-50mg/□□□) • □□□□□□□□□□□□ **(B2)** (25-50mg/□□□) • **TMG (**□□□□□□□□□□□□□□□□□□□□**)** (500-1000mg/□□□) — □□□□□□□□ □□□□□□□□ □□□□□

⚠ □□□□□□ □□□□□□□ — □□□-□□□□□□□□ □□□□□ □□ □□□□□ □□ □□□□ □□□□□ □□□-□□□□□□□□ □□□□□, □□□□□□□□□□□ □□ □□□□□□□ □□ □□□□ □□ □□□□ □□□ 2-4 □□□□□□

□□□ □□□□-□□□□ □□□□□□□ □□□ □□□-□□□□□□□□ □□ □□□□□ □□□□□, □□ □□□□□ □□ □□□□ □□ □□□□□□□ (50-100mg) □□□□□□□

□□□□□□ 3: □□□□□□□ □□□□□□

COMT □□ □□□□□□□ □□□□□□□□□□□

3.1 COMT □□□ □□?

COMT □□□ (Catechol-O-Methyltransferase) □□ □□□□□□ □□ □□□□□ □□□□ □□ □□ □□□□□□ □□:

• □□□□□□□□ • □□□□□□□□□□□□ • □□□□□□□□□□ • □□□□□□□ □□□□□□□□□

rs4680 □□□□□□□ (Val158Met) □□ □□□□□□ □□ □□□ □□□□□□□□□ □□□□ □□□

3.2 □□□□□□-□□□□□ □□□□□□□□□□

Val/Val — □□□□□□

□ □□□□□ □□□□□□ — □□□□ □□□□□□□□ □□□□□□□□□: • □□□□ □□□□□□□ □□□□□□□□ (Met/Met □□ 4x □□□□) • □□ □□□□□□□ □□□□□ • □□□□□ □□□□ □□□ □□□□□□□□ • '□□□□' □□ '□□□□□□□□' □□□ □□□□ □□

□□□ □□ □□□□□: • '□□□□□□□' □□□□□ □□□□ □□ □□□ □□□□□□□ □□□ □□□□ □□ • □□□□□□□□ □□□□□□□ □□□□ □□ □□□ □□□□□-□□□□ □□□□ □□□□□□□ • □□□□□□□ □□□□□□□□□□ □□ □□ □□□□□□□□

□□□□□□ □□ □□□□: • □□ □□□□□□□□□ □□□□□□□ □□□□□ • □□□□□□□□□ □□□□□□□ □□ □□□□□ □□□□□ □□□□ □□ • □□□□□-□□□□□□□ □□□□□□□ □□ □□□□□ □□ □□□□□□□□□

Met/Met — □□□□□

□ □□□□□ □□□□□□ □□□□□□ □□□□□ — □□□□ □□□□□□□□□ □□□□□□□□□: • □□□□ □□□□□□□□ □□□□□□□□□ • □□□□ □□□□□□□ □□□□□ • □□□□ □□□□□□□ □□□ □□□□ □□□□□□□□□□□□ □□□□□□□ □□ □□□ □□□□□□□□ • □□□□□ □□□□ □□ □□□□□□

□□□ □□ □□□□□: • □□□□□□□□ (□□□□, □□□□□□, □□□□□□□) □□ □□□ □□□-□□□ • □□□□□□□ □□□□□□ □□□□□ □□□□ □□□□ □□□ • □□□ □□□□□□ □□ □□ '□□□' □□□□ □□ □□□ □□□□□□□□ □□ □□□□□ □□ □□□□ □□

□□□□□□ □□ □□□□□□□□□: • □□□□□ □□□□□□□□□ □□□□□□□ □□□□□ • □□□□□-□□□□□□□ □□□□□□□ □□ □□□□□ □□□□ □□□□□□□ • □□□□, □□□□□□ □□□□□□ □□□□□□□ □□ □□□□□□□□

3.3 COMT □□□□□□ □□□□□□□□□

Val/Val (□□□□□□) □□ □□□

□ □□□□□ □□□□□□ — □□□□□□□□ □□□□□□ □□□□□ • **L-**□□□□□□□□ (500-1000mg □□□□, □□□□ □□□) • □□□□□□□□ □□□□□□□□□□ (15% L-DOPA, 100-200mg) • □□□□□□□□ □□□□□□□ (200-400mg) • □□□ □□□□□□□ □□□□□□ □□□ □□ □□□□□□□□ □□□□□□ □□ □□□

Met/Met (□□□□□) □□ □□□

□ □□□□□ □□□□□□ — □□□□ □□□□ □□□□ □□□□□ • □□□□□□□□□□ □□□□□□□□□□ (400-600mg/□□□) • **L-**□□□□□□ (200-400mg □□□□□□□□□□□□□□) • □□□□□□□□□□□□□□□□□□ (300mg □□□) • □□□□□□□□ (300-600mg, KSM-66 □□□□□) — □□□□□□□□ □□□ □□□□□□□□ □□□ □□ □□□□□□□□ • □□□□: □□□□□□□ □□□□□, □□□□□□□, □□□□□ □□□□□□□

□□□□□□ 6: □□□□□□□□□□ □□□□□

□□□□ □□□□□□□ □□ □□□□□ □□□□ □□□□□□□ □□□□□□□ □□□□

6.1 □□□□□□□□□□□: □□□□ □□□□□□□□ □□ □□□ □□□□□□□□

□ □□□□□□□□□□ □□ □□□ *□□□□ □□□ □□□□□□□□ □□□□ □□□□□□□□□□□ □□□□□□□□ □□□ □□ □□□□□□□□ □□□□ □□□ □□□□, □□□□□ □□ □□□□□□□□ □□ □□□□□□□□□ □□ □□□□ □□□□ □□□□□□□ — □□□□, □□□□□□□, □□□□, □□□□ — □□□□ □□□ □□ □□□□□□□□□ □□ □□□□□□□ □□□□ □□□*

□□□□□□□□□□□□ □□□□□ □□ □□ □□□□ □□□□□□□□ □□□□ □□ □□□□□ □□ □□□□ □□□ □□□□□□ □□□□□ □□ □□□□ □□□□ □□□□ □□□□□□□□ □□ □□□□□□ □□□ □□□ □□ '□□' □□ '□□' □□□□ □□□□

6.2 COMT □□□□□□□□ □□ □□□□□□ □□□□□□□□ □□□□□□□

Val/Val (□□□□□□□) □□ □□□

□ □□□□□ □□□□□□ — □□□□□□ □□□□□□□ □□□□□□□: □□□□ □□□□□□□, □□□□□□□□□□□□, □□□ □□□□□□□□□ (□□□□□□□, □□□□□□, □□□□□□) □□□□: □□□□ □□□□□□□ □□□ □□ □□□□ □□, □□□□□□□□ □□ □□□□□ □□ □□□□□□□□□ □□□□/□□□: □□□□□ □□□ □□□, □□□□□□□ □□ □□ □□□□ □□ □□□□□: □□□□ □□□□ □□□□ □□□□□□□ □□□ □□□□□ □□□□□□□□ □□□□ □□ □□□□□□□: □□□□□□□□□□, □□□ □□□□□□□□, □□□□□□ □□ □□□□□□□□

Met/Met (□□□□□) □□ □□□

□ □□□□□ □□□□□□ — □□□□□ □□□□□□□ □□□□□□□: □□□□□, □□□, □□□□□□, □□□□ □□ □□□ □□□□: □□□ □□ □□□□□□□□ □□□□□ □□□□, □□□□ □□□□ □□□□□ □□□□□□□□ □□ □□□□ □□□□/□□□: □□□□□ □□ □□□□ — □□□□□ □□□□□□ □□ □□□□ □□ □□□□□: □□□□, □□□□□□ □□□□□□□ □□□ □□□□□ □□□□□□□□ □□□□ □□ □□□□□□: □□□□□, □□□□□□□□□□□□, □□□□□□□□□ □□□□□□□ □□ □□□□□□□□

6.3 MTHFR □□□□□□□□□ □□□□□□□

□ □□□□□ □□□□□□ — **MTHFR T/T** □□ □□□ □□□□ □□□□□□□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□□: • □□□ □□□□□□□□ □□□□□□□□ (□□□□, □□□□, □□□□□) • □□□□ (□□□□ □□□□□□□□ □□□□□) • □□□□□ (□□□□, □□□, □□□□□) • □□□□□□, □□□□□□□□, □□□□□□□□ □□□□□□□□□□

□□□□: • □□□□□□□□ □□□□□ □□□□ (□□□ □□□□□□□□□□ □□□□□ □□□□□□□□ □□□) • □□□□ (□□□□□ □□ □□ □□□□ □□) • □□□□□□ □□□□ (□□□□□□□□ □□ □□□□ □□□□□□ □□)

6.4 □□□□□□□□ □□ □□□□□□ □□□□□ □□□□□□□□□

□□□□□□ □□□□□□□□□ (Val/Val)

□ □□□□□ □□□□□□ — □□□□□-□□□□□□ □□□□□□

1. □□□ □□□□□□: □□□□□□ □□□ □□ □□□□□, □□□ □□□□□□□□
2. □□□ □□□□□□□: □□□ □□ □□□□□□ □□ □□□□□□□□ □□□□□□
3. □□□□□□ □□□□□□□□□□□□□: □□□, □□□□□, □□□□□□□□□
4. □□□□□ □□□□□□: □□□□□□ □□□□□□□□, □□□□ □□□ □□□□□ □□□□□□

5. □□□□□□□□□□□□□□ □□□□□□□□□: □□□□ □□□□□□, □□□□□□□ □□□□□□□□□□□□□

□□□□□□ □□□□□□□□□□ **(Met/Met)**

□ □□□□□□ □□□□□□□ — □□□□□□□□-□□□□□□□ □□□□□□□

1. □□□□□ □□□□□□□□: □□□□□□ □□□□□□ □□□□□□□□□ □□ □□□□□
2. □□□□□□□□□□□□□ □□□□□□□□□: □□ □□ □□□□□□ □□ □□□□, □□□□□, □□□□□
3. □□□□□ □□□□ □□□□: □□□□□□, □□□□□□□□□□, □□□□
4. □□□□□□□□□□ □□□□□□□: □□□□□□□ □□ □□□□□ □□□□□□□□□□ □□□□□□□
5. □□□□□ □□□□□□□□: □□□□□□ □□□□□□□□□□□ □□ □□□□□

□□□□□□□□ A

□□□□□□□ □□□□□□ □□□□□□□□

□□□□□□□ A.1: CYP2D6 □□□□□□□□□□ — □□□□□□□□□

□□□□□□□	PM	NM	UM	□□□□□
□□□□□	□ □□□□□□□□	□ □□□□	☠ □□□□□□□□	PM: □□□□□□□ □□□ □□□□□□□□ □□□□□ UM: □□□□ □□□□ □□□□□□□□
□□□□□□□□ □	□ □□□□□□□□	□ □□□□	⚠ □□□□□□□□□ □□□□□	□□□□□ □□ □□□□
□□□□□□□□ □□	⚠ □□ □□□□□□	□ □□□□	⚠ □□ □□□□□□	□□□□□ □□□ □□ CYP2D6 □□□□□□ □□□□□□□□□□□
□□□□□□□	□ □□□□	□ □□□□	□ □□□□	CYP2D6 □□ □□□□□□□□ □□□□
□□□□□□□□	☠ □□□□□ □□□□□□	□ □□□□	□ □□□□	CYP2D6 □□ □□□□□□ □□□□ □□
□□□□□□□□ □□□□□	□ □□□□	□ □□□□	□ □□□□	CYP3A4, CYP2D6 □□□□
□□□□□□□	⚠ □□□□□□□□	□ □□□□	⚠ □□□□□□□	CYP2B6, CYP3A4

□□□□□□□ A.2: COMT/MTHFR □□□□□□□

COMT	MTHFR	□□□□□ □□□□□□□□	□□□□□□□ □□□□□	□□□□□□□□
Val/Val	C/C	□□	□□□□□□□, □□□□□□	□□□□□□□ □□□□□□□□□□
Val/Val	T/T	□□□□□	□□□□□□□, □□□□□	□□□□□□□□□□ + □□□□□□□□□□

COMT	MTHFR	[illegible]	[illegible]	[illegible]
Met/Met	C/C	[illegible]	[illegible], [illegible]	[illegible] [illegible]
Met/Met	T/T	[illegible]	[illegible], [illegible]-[illegible]	[illegible] + [illegible] + [illegible] [illegible]

[illegible] B

[illegible] [illegible] [illegible] AI [illegible] [illegible]

[illegible] [illegible] [illegible] *AI [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] LLM [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□□□□□□□□ □□□□□□□: • **AASRA**: 9820466726 (24/7) • □□□□□□□ □□□□□□□: 044-24640050 (□□□□□□□, 24/7) • **iCall**: 9152987821

□□□ □□□□□□□ □□ □□ □□□□□□□: • **NIMHANS** □□-□□□□□□□□ □□□□□□: □□□□□□□□ — 080-26995000 • **AIIMS** □□-□□□□□□□□ □□□□□□□□: □□□□□□□ — 011-26588500 • **TTK** □□□□□□□□□: □□□□□□□ — 044-28132000 • □□□□□□□□□□ □□-□□□□□□□□ □□□□□□: □□□□□ • □□□□□□ □□□□□□□: □□□□□□

□□□□□□□ □□□□□□□: • □□□□□□□□□□ □□□□ □□□□□□□ □□□□□□□□□□: 1800-11-0031 (□□□-□□□□□) • □□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□ **(DMHP)**: □□□□□ □□□□□□□ □□□□□ □□□□□□□□ □□ □□□□□□□ □□□□□ • **NIMHANS** □□□□□□□□□□□□□: nimhans.ac.in

□□□□□□□ □□□□□: • □□□□□□□□□□□□□ □□□□□□□□ □□□□□□□: aaindia.org | □□□□□□□□ □□□□□□□ □□ □□□□ □□□□□□□□ □□□□□□ • □□□□□□□□□□□ □□□□□□□□ □□□□□□□: naindia.org | helpline@naindia.org

□□□□□ □□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□: • □□□□□□□ □□□□□□□□□□□□□ □□□□□□ □□□□ □□□□□□□: Mapmygenome, Medgenome, Strand Life Sciences • □□□□□: □□□□□ □□ □□□□□□□ ₹15,000-40,000 • □□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□ □□□□□ □□□□ □□□ □□ □□□□□ □□□□ • AIIMS □□ NIMHANS □□□□ □□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□ □□ □□□□□ □□□□

□□□□□ □□□□

□ □□□□□□□□□□□ □□ □□□□□□ □□□□

□□ □□□□□ □□□□ □□□□□ □□□□□
□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□ □□□□□ □□□□□□□□□□ □□ □□□□ □□□□□□□□□□□ □□□□□ □□□□
□□ □□□□□□ □□□□□ □□□□□ □□□□□□□ □□□□
□□ □□□□□□□□ □□ □□□□, □□ □□□□□ □□□□□□□□□ □□ □□□□ □□□□□□
□□ □□□□ □□□□□□□ □□□□ □□□□□ □□□□ □□ □□□□ □□□□ — □□□□□ □□□□, □□□□□□ □□□□ □□ □□□□□ □□□□□□□□□□ □□ □□□□□
□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□
□□□□□ □□□□□□□ □□□□ □□□□□ □□□□□□□ □□□□
— □□.□□. □□□□□
□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□

⚠ □□ □□ □□□□□ □□□□□□□□□□ □□□□□□□ □□ — □□□□□□□□□ □□□□□ □□□□□ ⚠

[illegible]

© [illegible]

THE RECOVERY KERNEL: [illegible]

[illegible]